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Objectives. The endovascular aneurysm repair (EVAR) trials aim to assess the efficacy of EVAR in the treatment of AAA in
terms of mortality, quality of life, durability and cost-effectiveness.
Design. Male and female patients aged at least 60 years with an AAA diameter measuring at least 5.5 cm on a computed
tomography (CT) scan are assessed for anatomical suitability for EVAR. Suitable patients are offered entry either into EVAR
Trial 1 if they are considered fit for conventional open repair or EVAR Trial 2 if they are considered unfit. EVAR 1 randomly
allocates patients to EVAR or open repair and EVAR 2 randomly allocates patients to EVAR with best medical treatment or
best medical treatment alone. Target recruitment for EVAR Trials 1 and 2 is 900 and 280 patients, respectively.
Progress. Recruitment began in September 1999 and there are currently 40 UK centres participating in the trials. Monthly
targets are being exceeded in EVAR Trial 1 with 1037 patients randomised by October 2003. EVAR Trial 2 is also meeting
monthly targets with a total of 319 patients randomised. When recruitment closes in December 2003 patients will need to be
followed for at least 1 year from their operation. Publication of full results for both trials is expected in mid 2005.
Key Words: Abdominal aortic aneurysm; Randomised controlled trial; Endovascular aneurysm repair.
Introduction
The incidence of abdominal aortic aneurysm (AAA) in
England and Wales has been increasing. From 1950 to
1984 age standardised mortality rose 20-fold in men to
47.1 per 100,000 population per year and 11-fold in
women to 22.2 per 100,000 per year.1 These data were
based on hospital admissions for aortic aneurysmal
disease and the increase could only be partially
explained by the introduction of surgical treatment
for AAA and the use of more accessible imaging
modalities. Similar trends have been noted in North
America, elsewhere in Europe and Australasia and so
there appears to be a true increase in the incidence of
AAAs. In the early 1990’s Parodi, Palmaz and Barone
in Argentina2 and Volodos in the Ukraine introduced
endovascular aneurysm repair (EVAR). These pio-
neers used hand made stent graft systems beginning
with a repair to lie entirely within the abdominal aorta
(aorto-aortic graft). Subsequently it was shown that
the aorto-aortic endovascular grafts were applicable in
less than 10% of patients and bifurcation systems were
developed which enable a greater proportion of
aneurysms to be managed by an EVAR method3 ‘In-
house systems’ were introduced in this country in
Nottingham4 and Leicester.5 These systems employed
an aorto uni-iliac stent graft system made in house
with the second side being occluded using a Dacron
sac and stent and the procedure completed with a
femoro-femoral crossover graft. This left patients with
two small incisions in the groins and minimum pain.
During the last 5 years the use of in-house systems has
been usurped by commercially available systems as
technological improvements have made them a more
viable choice of treatment.
The UK registry for endovascular treatment of aneurysms
(RETA)
The National RETA registry, based at the Northern
General Hospital in Sheffield, was initiated in January
1996 to audit ‘in-house’ and commercially available
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The UK endovascular aneurysm repair (EVAR) trials are two
randomised controlled multi-centred studies that aim to assess the
efficacy of EVAR in patients considered fit or unfit for conventional
abdominal aortic aneurysm (AAA) surgery in terms of mortality,
cost effectiveness, graft durability and health related quality of life.
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EVAR systems deployed within the UK.6 Annual
audits have been conducted and reports are made
available to the EVAR Trial Management Committee
(TMC), principally to be advised when centres are
trained. This EVAR TMC meets regularly to monitor
progress of the trials and demands that each centre has
performed at least 20 EVAR procedures according to
RETA, before they are able to participate in the trials.
Each centre is required to nominate a vascular
surgeon, interventional radiologist and trial co-ordi-
nator as trial participants for their hospital.
EUROSTAR
The EUROSTAR project was launched in 1996 to audit
prospectively the performance of EVAR across 14
European countries.7 In 1999, a long-term durability
analysis of EVAR was performed on 1930 patients
from this registry that demonstrated a 1% annual
rupture rate for EVAR devices deployed in small and
large aneurysms across Europe.8 A similar rupture
rate was observed during surveillance of patients
randomised in the UK small aneurysm trial9 and
although the studies are quite different there is a
concern that EVAR may do little to improve upon the
natural history of small AAA.
The UK small aneurysm trial
The results of the UK small aneurysm trial were
reported in two back-to-back papers published in The
Lancet in November 1998.9 The 30-day operative
mortality for patients randomised to elective surgery
in the UK small aneurysm trial was 5.8% and an
annual rupture rate of 1% was found during surveil-
lance. Accordingly, no benefit was found for early
surgical intervention. More recently, the New England
Journal of Medicine has published a long-term
analysis of the data in the UK small aneurysm trial
and the authors concluded that there is still little
advantage in offering early elective surgery to patients
with small aneurysms.10 For this reason, the diameter
threshold of 5.5 cm has been adopted for entry into the
EVAR trials.
EVAR is currently being used both for fit for open
repair patients (<75%) and unfit for open repair
patients (<25%). Consequently it is appropriate to
pose the question “what is the cost effectiveness of
aortic stenting versus other innovative methods versus
open repair for elective AAAs”? Disregarding the less
developed innovative techniques which include
laparoscopic AAA repair, the important goal is to
evaluate the mortality, durability and cost-effective-
ness associated with EVAR, open repair and best
medical therapy in fit and unfit patients with AAA
diameters$5.5 cm. This is the basis of the EVAR trials.
Materials and methods
Generalisability and the EVAR study
It is of particular importance that patients found to be
unsuitable for an EVAR device are recorded. Numbers
of unsuitable patients are logged and reasons for
unsuitability are recorded in order to determine what
proportion of AAA patients are anatomically suitable
for an EVAR device at the national level. Thus, all
patients registered for assessment of anatomical
suitability for an EVAR device form the ‘EVAR
Study’ and trial patients are drawn from this pool of
AAA patients. Some of the eligible centres act as both
the ‘local’ and ‘regional’ centre for their area and
therefore patient postcodes are being collected to
monitor referral patterns.
Entry criteria
Age at least 60 years
A minimum age of 60 years was chosen as surgeons
may wish to manage patients under 60 years in a
different way because frequently there is an associated
genetic cause where expansion rates and extent of
aortic aneurysm may be extreme, such as Marfan
syndrome.11 No upper age limit is thought necessary
as very elderly patients may benefit from the use of an
EVAR device and their recruitment will be important
for achieving the numbers required.
Size of abdominal aortic aneurysm
The criterion for entry into both trials is an aneurysm
diameter measuring $5.5 cm according to a CT scan.
However, reproducibility differences between Duplex
ultrasound and CT scanners can lead to significant
variation in AAA diameters. Duplex scanning tends to
produce AAA diameters smaller than CT scanning
and therefore we recommend that patients presenting
with a $5.0 cm aneurysm on Duplex should be sent
for a CT scan to determine whether the aneurysm is
$5.5 cm in any diameter on CT scan and thus suitable
for EVAR trial entry. Tender aortic aneurysms and
contained ruptures may be included provided the
aneurysm measures at least 5.5 cm on a CT scan and
suitable EVAR equipment is available at short notice.
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Anatomical suitability for EVAR
This is assessed by spiral CT or conventional CT
combined with conventional angiography with a
marked catheter to enable the calculation of aortic
length. The trial co-ordinator works closely with the
local radiologist and appropriate training centre and
documents how the aneurysm is assessed and how the
size and type of EVAR device is selected.
Choice of device. Participating centres are free to
decide which commercial or in-house devices to
use although the use of commercially available
devices is favoured. These all carry the CE mark
and are therefore freely available on the market and
have undergone certain checks before being
released. It is assumed that each centre will take
the time to discuss the evidence for the safety of
each device with the company. The anatomical
suitability of EVAR devices will therefore be very
centre-specific depending on the number of devices
that they chose to use in that hospital. It is not
feasible for the trial protocol to intrude on the
choice of device at each centre and this has been left
as a pragmatic decision for the participating
clinicians.
Fitness for surgery
This is determined locally by the surgeon, radiol-
ogist, anaesthetist and cardiologist. It was originally
thought that ASA grades I, II and III would indicate
entry to EVAR Trial 1 and ASA IV patients would
permit entry into EVAR Trial 2. However, despite
the simplicity of ASA grading it can be open to
wide interpretation at each centre and proved too
difficult to use as a classification system for EVAR
Trial 1 or 2. Recently, more sophisticated tests have
not been good predictors of outcome in vascular
surgery.12 It has been appreciated during the UK
small aneurysm trial that fitness ‘inflation’ emerged
with respect to the size of aneurysm. Patients who
were earlier described as ‘unfit for OR’ and later
developed a larger aneurysm were suddenly
deemed ‘fit for the procedure’. This could equally
happen for these current trials and for the purposes
of pragmatism, fitness is determined at the local
level. Recommended cardiac, respiratory and renal
guidelines are provided as outlined in Fig. 1 and
baseline data will be used to assess fitness of
randomised patients at the final analysis. These
guidelines may help provide some conformity of
fitness classification for EVAR Trial 1 or 2. Further-
more, randomisation is stratified by centre and this
should ensure that any differences in assignment of
fitness status between centres should not lead to
any considerable differences between randomised
groups.
Randomisation
Randomisation is performed for each trial using 50:50
ratio randomly permuted block sizes constructed by
the STATA package. Randomisation is stratified by
centre and is only performed when all necessary
baseline data have been received at Charing Cross.
This enables patients to be randomised into the
relevant trial and simultaneously flagged for mortality
at The Office for National Statistics. Centres are
encouraged to perform surgery within a month of
randomisation.
Fig. 2 demonstrates the entry protocol for patients
into both trials.
Outcome measures
The primary endpoint for both trials is all-cause
mortality.
All-cause mortality for EVAR Trial 1
Patients randomised to open repair in the UK small
aneurysm trial experienced an annual all-cause mor-
tality of 7.1%. In the EVAR trials, patients are under-
going AAA repair for larger aneurysms and we have
assumed an annual mortality rate of 7.5%. If EVAR can
reduce this mortality to 5% per year then EVAR might
be justified as a viable treatment alternative for AAA.
By the end of the recruitment phase on 31st December
2003 we aim to have randomised at least 900 patients
into EVAR Trial 1. Patients will be followed until April
2005 and this will accumulate an average follow-up of
3.33 years per patient. This produces 80% power at the
5% significance level.
All-cause mortality for EVAR Trial 2
Patients with large AAA considered unfit for open
repair in the UK small aneurysm study were followed
up for AAA growth and rupture and were shown to
have an annual all-cause mortality of 25%. The RETA
registry has shown that patients considered unfit for
open repair who have been treated with EVAR have an
annual all-cause mortality of 15%. By the end of the
recruitment phase on 31st December 2003 we aim to
have randomised at least 280 patients into EVAR Trial
2. Patients will be followed until April 2005 and this
will accumulate an average follow-up of 3.33 years per
patient. This produces 93% power at the 5% signifi-
cance level to detect a difference of 10% between the
two treatment regimes.
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30-Day operative mortality
From the UK small aneurysm trial data, 30 day
operative mortality was calculated for patients who
were randomised to observation but whose aortic
aneurysms subsequently grew to .5.5 cm when
surgery was performed ðn ¼ 191Þ: Eleven were dead
at 30 days leading to a 30-day operative mortality of
5.8%. Power calculations for 30-day operative mor-
tality in EVAR Trial 1 were based on 90% power at the
5% significance level using 5.8% for open repair and
1.5% for EVAR and these indicated that 443 patients
would be required in each arm leading to a total of 900
patients to detect this difference should it exist.
Graft durability
The incidence of endoleaks and rupture from
EVAR devices and rupture of grafts in patients
who have undergone an open repair is being
monitored. The long-term durability of open repair
procedures is being scrutinised as well as EVAR
device performance as follow-up of patients in the
UK small aneurysm trial detected a number of
AAA ruptures as the cause of death in patients
who were known to have had an open repair. CT
scans are being performed annually to record the
sac and anastomosis diameter measurements in
open repair patients.
Fig. 1.
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Endoleaks in EVAR patients are classified according
to an amended version of the Geoffrey White (Sydney,
Australia) classification:13
Endoleak type I. Perigraft leak, perigraft channel or
graft-related endoleak at proximal or distal end.
Endoleak type II. Retrograde endoleak, collateral flow,
retroleak or non-grade related endoleak. Leak from
patent lumber, inferior mesenteric, intercostal
teries.
Endoleak type III. Fabric tear, modular disconnection or
poor seal endoleak of undefined source.
Incidence of graft migration, rupture, anastomotic
aneurysm, thrombosis, stenosis and infection is also
being monitored. The Medical Devices Agency are
working closely with the data monitoring and ethical
committee.
Health related quality of life (HRQL)
In measuring HRQL a combination of specific and
generic instruments was recommended.14 Specific
instruments are useful for clinical evaluation; their
narrow focus makes them more responsive to small
but clinically important changes in health. Generic
instruments are useful for economic evaluation and for
comparisons across groups of patients; their compre-
hensive nature also enables them to detect unforeseen
effects of treatment. There are two main types of
generic instrument—health profiles and utility
measures. Health profiles measure HRQL across a
number of distinct dimensions and thus assess the
effect of healthcare on different aspects of HRQL.
Utility measures incorporate the values that individ-
uals attach to HRQL and thus produce a single
index of HRQL suitable for economic evaluation.
The portfolio of instruments to measure HRQL in
Fig. 2. Summary of recruitment procedure for EVAR trials.
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the proposed trials was designed to be comprehensive
yet brief. This portfolio is completed by patients in the
form of a questionnaire—at recruitment and sub-
sequently 1, 3 and 12 months after surgery or the
beginning of medical treatment as appropriate. The
questionnaire includes three generic instruments—the
Short-Form 36-item (SF-36) Health Survey,15 EuroQol
and the State-trait Anxiety questionnaire assesses
patient anxiety. The SF-36 has been shown to be
valid, reliable and responsive to changes in health in
British patients.16 – 18 The EuroQol is a validated utility
measure comprising five items covering mobility, self
care, usual activities, pain, anxiety and depression.19
The HRQL states defined by the various combinations
of responses to these items have been valued by 3395
members of the general public for use in cost-utility
analysis.20 Unfortunately there is no specific instru-
ment designed to measure HRQL in patients suffering
from AAA. In this circumstance we have proposed to
use one specific instrument, the patient generated
index (PGI). This is a quasi-specific HRQL instrument
that focuses on the concerns of the individual patient
with a given condition rather than concerns derived by
the investigator for the typical patient with that
condition.21 Patients nominate and rate on a scale the
five most important aspects of their lives affected by
their condition. The final score represents the gap
between their current health status and their expec-
tations in those areas of their lives in which they would
most value an improvement. Thus the PGI measures
the effect of the condition on quality of life as defined
by the patient. There is good evidence for the
acceptability, validity, reliability and responsiveness
of this instrument.
Economic evaluation
Introduction. Various investigations have been pub-
lished comparing the costs associated with endovas-
cular versus open repair.22 – 25 The overall aim of the
analysis will be to estimate the cost-effectiveness of
alternative treatment strategies as part of a random-
ised trial of patients with AAA. The economic analysis
will carry out two comparisons:
(a)Endovascular aneurysm repair (EVAR) versus open
repair in patients fit for open repair; and
(b)EVAR plus best medical management versus
medical management alone in unfit patients.
Outcome measures. The primary outcome measure for
the economic analysis will be the Quality-Adjusted
Life Year (QALY), calculated using patients’ replies to
the EuroQol (EQ-5D) questionnaire administered at
baseline, 1 and 3 months and annually thereafter until
the end of follow-up. QALYs are then estimated using
the area under the curve method of utility against
time.26 Other outcome measures used in the trial (SF-
36, PGI) will be compared to the EQ-5D to establish
whether consistent results are evident between
measures.
Resource use and unit costs. The estimation of the
differential costs between EVAR and its relevant
comparator involves a two-stage process. The first
stage is to measure resource use in physical units as
used by trial patients and centres. Operating pro-
cedure data will be collected on the type of graft used,
time in theatre, units of blood transfused and length of
stay in hospital. The number of adverse events and
admissions to hospital for reasons related to their
AAA for each patient is collected at each follow-up.
The second stage is to cost these resource use data
using prices or unit costs at the time of the analysis.
Where possible, the aim in the primary analysis is to
apply local unit costs faced by the hospital in which
the patient was treated. National UK unit costs will be
applied as a sensitivity analysis. The sources of unit
costs will include the trial hospitals themselves and
routine or published literature, for example, NHS
reference costs, medical device manufacturers, NHS
salary scales.
Hospitalisations for reasons other than AAA, use of
healthcare in community settings, medical manage-
ment (e.g. drugs) and days lost to normal activity will
not be collected in the trial.
Statistical analysis. Given the likely skewness of the
distributions of the cost and QALY data, non-para-
metric bootstrapping techniques will be used to
provide reliable estimates of the standard errors
associated with these variables.27 Appropriate impu-
tation techniques will be used to handle missing data28
and methods will also be required to deal with
censored cost data resulting from staggered recruit-
ment into the trial.29
Standard decision rules will be used to assess the
cost-effectiveness of the intervention relative to the
comparator treatment.30 Sampling uncertainty around
the estimates of mean differential cost and QALYs will
be represented by using cost-effectiveness acceptabil-
ity curves.31 These curves show the probability that
EVAR is more cost-effective than its comparator as a
function of maximum value attached to an additional
QALY generated in these patients.
Regression analysis. Using multiple regression anal-
ysis, baseline covariates will be used in order to
explain variability in costs and outcomes, increase the
precision of estimates and estimate the marginal cost-
effectiveness of the intervention in appropriate sub-
groups of patients who will be clearly defined prior to
the analysis.
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It is expected that cost-effectiveness data will exhibit
some degree of clustering, that is, patients within the
same hospitals are more alike than those from other
hospitals. Multi-level modelling techniques will be used
to examine whether the hospitals’ characteristics have
an impact on patient outcomes and costs.
The benefit of using a multi-level modelling
approach over traditional multiple regression is that,
whilst either will give unbiased estimates of differen-
tial mean costs and QALYs, only multi-level models
give accurate estimates of their standard errors. In
addition, in accounting for the relative impact of
hospital characteristics on the estimates of mean costs
and QALYs, multi-level analysis will facilitate the
exploration of the generalisability of the cost-effective-
ness results across the hospitals involved in the EVAR
study.
Follow-up
All trial patients are flagged for mortality at The Office
for National Statistics (ONS). HRQL data are collected
at 1, 3 and 12 months following treatment and cost
evaluation data have been based on operation costs
and graft durability issues during the course of follow-
up. Any adverse events are also collected, e.g. tender
AAA, ruptured AAA, conversion to open repair,
myocardial infarction, stroke, renal failure and ampu-
tation. CT scans are used for assessment of growth
rates, persistent endoleaks and durability, which could
vary with stent graft type. Centres are encouraged to
provide data from as many CT scans as possible but
the minimum requirement is for CT scan follow-up is
at 1 and 3 months post EVAR procedure for EVAR
patients and then annual scans for all randomised
patients in each arm of both trials. Centres are free to
utilise any additional imaging modality beyond CT
scan if it is felt appropriate, however, data are not
collected for this additional imaging as the CT scan
form can be used to record any problems that have
been identified with the AAA or graft.
Recruitment and progress
By 31st October 2003, 4482 patients had been regis-
tered into the EVAR study. Suitable patients have been
drawn from this pool of EVAR study registrations and
randomised into EVAR Trial 1 (1037 patients) or EVAR
Trial 2 (319 patients). Patients who do not enter the
trials are excluded for various reasons including
unsuitability for an EVAR device, AAA ,5.5 cm on
CT scan, refusals for entry into either trial or refusals
for any CT scan or further treatment. Recruitment rates
vary considerably between the 40 centres with some
hospitals more enthusiastic about EVAR Trial 2 than
others. Fig. 3(A) and (B) shows cumulative recruit-
ment into both trials. EVAR Trial 1 has recruited
consistently ahead of target and is expected to recruit
1100 patients by the end of December 2003. Recruit-
ment into EVAR Trial 2 tended to fall short of the target
rate during the early phase of the trial but patients are
now being recruited ahead of target and the final trial
size is expected to reach 330 patients by December
2003. During the last 2 years there has been a notable
increase in the recruitment of patients into EVAR Trial
2 and it is not clear why there has been this change in
enthusiasm. Certainly, recent reports of the possible
long-term durability problems associated with EVAR
devices have perhaps raised a certain level of caution
amongst both surgeons and interventional radiol-
ogists. Patients that are considered unfit for open
repair have a very poor long-term prognosis as was
shown in a sub-set of patients in the UK aneurysm
study where 50% of patients with aneurysms larger
than 5.5 cm who were unfit for conventional surgery
died within 2 years of follow-up. There is currently no
evidence to suggest that the implantation of an EVAR
device alters the time of death for these unfit
individuals. The recent increase in recruitment into
EVAR Trial 2 may be a reflection of clinicians
uncertainty on how to proceed with such patients.
Recently, two other randomised controlled trials
investigating the role of EVAR have commenced,
namely the DREAM Trial based in Holland and the
OVER Trial based in the USA. The ACE Trial in France
has secured funding but has yet to start recruitment.
The EVAR Trials Data Monitoring & Ethical Commit-
tee have recommended that recruitment into the EVAR
Trials continues until the end of December 2003 as this
will lead to a surplus of patients beyond our targets
that will increase the precision of the trials and also
help to account for any cross-over patients who do not
adhere to trial protocol. In order to accrue sufficient
patient years of follow-up, a minimum of 1 year of
follow-up is required per patient and on this timescale
we might expect to publish the results of the trials in
mid 2005. However, a final publication date has not
been decided and further long-term follow-up of
EVAR devices may still be required before a formal
analysis is performed. In particular, it is important to
remember that endovascular treatment for AAA is an
evolving technology and the early generation devices
that were used during the first 6–8 months of the trials
will need to be compared to the later, more sophisti-
cated models. ‘Tracker trial’ methodology32 will be
used for this purpose as sub-group analysis would be
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inappropriate. The Data Monitoring and Ethical
Committee are scrutinising the data and will advise
the Trial Management and Steering Committees when
they feel it might be appropriate to publish the trial
findings.
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Fig. 3. (A) Cumulative recruitment of 1037 patients into EVAR Trial 1 up to 31st October 2003 (Target ¼ 900, Expected ¼ 1100
patients by 31/12/2003). (B) Cumulative recruitment of 319 patients into EVAR Trial 2 up to 31st October 2003. (Target ¼ 280,
Expected ¼ 330 patients by 31/12/2003).
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Leen, South Cleveland Hospital, Middlesborough; Mr
T.M.L. Loosemore, Dr A.M. Belli, St George’s Hospital,
London; Mr M. Adiseshiah, Dr J.A.S. Brookes, Uni-
versity College Hospital, London; Mr R.J. Whiston, Dr
A. Wood, University Hospital of Cardiff; Professor
C.N. McCollum, Dr R. Ashleigh, University Hospital
of South Manchester.
Trial Coordinators
Marion Aukett, Sara Baker, Emily Barbe, Jocelyn Bell,
Dee Boardley, Jo Blundell, Sheila Boyes, Oliver Brown,
Jennie Bryce, Tina Chance, Joanne Coleman, Chryz
Cosgrove, Trez Dennison, Carol Devine, Nikki
Dewhirst, Alison Dry, Barry Errington, Paul Fulford,
Moira Gough, Norma Gourlay, Sue Hamilton, Rona
Hooper, Jill Horne, Liz Horrocks, Bet Hughes, Tracey
Hutchings, Marilyn Ireland, Claire Judge, Linda Kelly,
Julie Kemp, Milla Kivela, Jeanette Lock, Asif Mah-
mood, Janis Martin, Shirley Murray, Allison Murtagh,
L. C. Brown et al.380
Eur J Vasc Endovasc Surg Vol 27, April 2004
Gareth Owen, Cathy Pitman, Jane Rowley, Julie
Sinclair, Nicky Sinclair, Sarah Spencer, Victoria Taylor,
Cindy Tomlinson, Karen White, Jenny Williams,
Lesley Wilson, Haney Youssef.
References
1 Fowkes FGR, MacIntyre CCA, Ruckley CV. Increasing inci-
dence of AA in England and Wales. BMJ 1989;298:33–35.
2 Parodi JC, Palma JC, Barone HD. Transfermoral intraluminal
graft implantation for abdominal aortic aneurysm. Ann Vasc Surg
1991;5:491–497.
3 Andrews SM, Cuming R, MacSweeney ST, Barrett NK,
Greenhalgh RM, Nott DM. Assessment of feasibility for
endovascular prosthetic tube correction of aortic aneurysm. Br J
Surg 1995;7:917.
4 Yusef SW, Baker DM, Hind RE et al. Endoluminal transfemoral
abdominal aortic aneurysm repair with aorto-uni-iliac graft and
femorofemoral bypass. Br J Surg 1995;82:916.
5 Nasim A, Thompson MM, Sayers RD, Bolia A, Bell PRF.
Endovascular repair of abdominal aortic aneurysm: an initial
experience. Br J Surg 1996;83:516–519.
6 Thomas SM, Gaines PA, Beard JD, On behalf of VSSGBI and
BSIR. Short term (30 day) outcome of endovascular treatment of
abdominal aortic aneurysms: results from the prospective
Registry of Endovascular Treatment of Aneurysms (RETA). Eur
J Vasc Endovasc Surg 2001;21:57–64.
7 Harris PL. The need for clinical trials of endovascular
abdominal aortic aneurysms stent/graft repair: the EUROSTAR
Project. J Endovasc Surg 1997;4:72–77.
8 Harris PL et al. Incidence and risk factors of late rupture,
conversion and death after endovascular repair of infrarenal
aortic aneurysms: the EUROSTAR experience. J Vasc Surg 2000;
32(4):739–749.
9 The UK. Small Aneurysm Trial Participants. Results for
randomised controlled trial of early elective surgery or ultra-
sonographic surveillance for small abdominal aortic aneurysms.
Lancet 1998;352:1649–1660.
10 The UK Small Aneurysm Trial Participants, Long-term outcomes
of immediate repair compared with surveillance of small aortic
aneurysms. NEJM 2002;346(19):1445–1452.
11 Muluk SC, Gertler JP, Brewster DC, Cambria RP et al.
Presentation and patterns of aortic aneurysms in young patients.
J Vasc Surg 1994;20(6):880–886.
12 D’Angelo J, Pappalo D, Farber A, Murphy AE, Faust GR,
Cohen Jon R. Is preoperative cardiac evaluation for abdominal
aortic aneurysm repair necessary? J Vasc Surg 1997;25:152–156.
13 White GH, May J. Failure of endovascular repair of abdominal
aortic aneurysms: endoleak, adverse events and grading of
technical difficulty. In: Greenhalgh RM, ed. The Durability of
Vascular and Endovascular Surgery. London: WB Saunders, 1999.
14 Streiner DL, Norman GR. Health measurement scales: a
practical guide to their development and use. Oxford: Oxford
University Press, 1989.
15 Ware JE, Sherbourne CD. The MOS 36-item short-form health
survery (SF-36): conceptual framework and item selection. Med
Care 1992;30:473–483.
16 Garratt AM, Ruta DA, Abdalla MI, Buckingham KJ, Russell
IT. The SF-36 health survey questionnaire: an outcome measure
suitable for routine use within the NHS? BMJ 1993;306:
1440–1444.
17 Ruta DA, Abdalla MI, Garratt AM, Russell IT. The SF-36
health survey questionnaire: reliability in patient populations.
Qual Health Care 1994;3:180–185.
18 Garratt AM, Russell IT, Abdalla MI. The SF-36 health survey
questionnaire: responsiveness to changes in health status in four
common clinical conditions. Qual Health Care 1994;3:186–192.
19 The EuroQol Group, EuroQol—a new facility for the measure-
ment of health-related quality of life. Health Policy 1990;16:
199–208.
20 Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol:
results from a UK general population survey. York Centre for Health
Economics Discussion Paper; 1995. pp. 138.
21 Ruta DA, Garratt AM, Leng M, Macdonald LM, Russell IT.
A new approach to the measurement of quality of life—the
Patient-Generated Index. Med Care 1994;11:1109–1126.
22 Bosch JL, Kaufman JA, Beinfeld MT et al. Abdominal aortic
aneurysms: cost-effectiveness of elective endovascular and open
surgical repair. Radiology 2002;225(2):337–344.
23 Patel ST, Haser PB, Bush HL, Kent KC. The cost-effectiveness
of endovascular repair versus open surgical repair of abdominal
aortic aneurysms: a decision analysis model. J Vasc Surg 1999;
29(6):958–972.
24 Sternbergh WC, Money SR. Hospital cost of endovascular
versus open repair of abdominal aortic aneurysms: a multicentre
study. J Vasc Surg 2000;31(2):237–244.
25 Lester JS, Bosch JL, Kaufman JA, Halpern EF, Gazelle GS.
Inpatient costs of routine endovascular repair of abdominal
aortic aneurysm. Acad Radiol 2001;8(7):639–646.
26 Matthews JNS, Altman DG et al. Analysis of serial measure-
ments in medical research. BMJ 1990;300:230–235.
27 Efron B, Tibshirani R. An Introduction to Bootstrap. New York:
Chapman and Hall, 1993.
28 Briggs A, Clark T et al. Missing…presumed at random: cost
effectiveness of incomplete data. Health Econ 2003;12(5):377–392.
29 Willan AR, Lin DY, Cook RJ, Chen EB. Using inverse-
weighting in cost-effectiveness analysis with censored data. Stat
Methods Med Res 2002;11:539–551.
30 Johannesson M, Weinstein S. On the decision rules of cost-
effectiveness analysis. J Health Econ 1993;12:459–467.
31 Van Hout BA, Al MJ, Gordon GS et al. Costs, effects and C/E-
ratios alongside a clinical trial. Health Econ 1994;3(5):309–319.
32 Lilford RJ, Braunholtz DA, Greenhalgh RM, Edwards SJL.
Trials and fast changing technologies: the case for tracker studies.
BMJ 2000;320:43–46.
Accepted 17 December 2003
The UK Endovascular Aneurysm Repair (EVAR) Trials: Design, Methodology and Progress 381
Eur J Vasc Endovasc Surg Vol 27, April 2004
